| Bioactivity | Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3ɛ. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines[1]. |
| Target | B cell maturation antigen, BCMA; CD3ɛ |
| Invitro | Pacanalotamab (1 pg/mL-100 ng/mL；24 h) 通过 T 细胞激活诱导 BCMA 依赖性肿瘤细胞裂解[1]。Pacanalotamab 诱导人多发性骨髓瘤细胞系的剂量依赖性重定向裂解，EC90 值范围为 16-810 pg/mL[1]。Pacanalotamab (100 ng/mL；24 小时) 诱导磷脂酰丝氨酸从质膜内层转移到外层，导致 MM.1R 细胞凋亡[1]。 |
| In Vivo | Pacanalotamab (50 µg/kg/天；静脉内或皮下注射；持续 18 天) 在小鼠 NCI-H929 异种移植模型中表现出抗肿瘤活性[1]。Pacanalotamab (5 µg/kg/天；静脉注射或皮下注射) 在小鼠原位 L-363 异种移植模型中显着延长小鼠的存活时间[1]。Pacanalotamab (静脉注射，135 µg/kg/天，或皮下注射，405 µg/kg/天；共 7 天) 耐受性良好，在毒性研究中它减少了猕猴骨髓中的浆细胞[1]。 Animal Model: |
| Name | Pacanalotamab |
| CAS | 2251756-52-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hipp S, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017 Aug;31(8):1743-1751. |